Skip to main content
Erschienen in: Der Internist 1/2012

01.01.2012 | Schwerpunkt

Herzfrequenz und Frequenzkontrolle

Prognostische Bedeutung bei kardiovaskulären Erkrankungen

verfasst von: Dr. F. Custodis, J.-C. Reil, U. Laufs, M. Böhm

Erschienen in: Die Innere Medizin | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Herzfrequenz ist ein kardiovaskulärer Risikoindikator. Insbesondere bei Patienten mit Herzinsuffizienz und möglicherweise auch bei koronarer Herzerkrankung ist eine erhöhte Ruhe-Herzfrequenz als unabhängiger Risikofaktor anzusehen. Klinische und experimentelle Arbeiten weisen darauf hin, dass die Herzfrequenz selbst direkte Wirkungen auf strukturelle und funktionelle Eigenschaften des Herz-Kreislauf-Systems, v. a. auf das Gefäßsystem, ausübt. Die Daten der SHIFT-Studie belegen den Stellenwert der Herzfrequenz als Risikofaktor und Therapieansatz bei Patienten mit chronischer Herzinsuffizienz: Zusätzlich zu einer leitliniengerechten medikamentösen Therapie reduzierte Ivabradin die Häufigkeit von Klinikeinweisungen aufgrund einer klinischen Verschlechterung und reduzierte zudem herzinsuffizienzbedingte Todesfälle. Die Daten der BEAUTIFUL-Studie zeigen, dass eine Herzfrequenz von ≥70 Schlägen pro Minute bei Patienten mit einer ischämischen Kardiomyopathie das Risiko für koronare Ereignisse erhöht.
Literatur
1.
Zurück zum Zitat Bassenge E, Heusch G (1990) Endothelial and neuro-humoral control of coronary blood flow in health and disease. Rev Physiol Biochem Pharmacol 116:77–165PubMed Bassenge E, Heusch G (1990) Endothelial and neuro-humoral control of coronary blood flow in health and disease. Rev Physiol Biochem Pharmacol 116:77–165PubMed
2.
Zurück zum Zitat Baumhäkel M, Custodis F, Schlimmer N et al (2010) Heart rate reduction with ivabradine improves erectile dysfunction in parallel to decrease in atherosclerotic plaque load in ApoE-knockout mice. Atherosclerosis 212:55–62PubMedCrossRef Baumhäkel M, Custodis F, Schlimmer N et al (2010) Heart rate reduction with ivabradine improves erectile dysfunction in parallel to decrease in atherosclerotic plaque load in ApoE-knockout mice. Atherosclerosis 212:55–62PubMedCrossRef
3.
Zurück zum Zitat Beere PA, Glagov S, Zarins CK (1984) Retarding effect of lowered heart rate on coronary atherosclerosis. Science 226:180–182PubMedCrossRef Beere PA, Glagov S, Zarins CK (1984) Retarding effect of lowered heart rate on coronary atherosclerosis. Science 226:180–182PubMedCrossRef
4.
Zurück zum Zitat Beuckelmann DJ, Nabauer M, Kruger C, Erdmann E (1995) Altered diastolic [Ca2 +]i handling in human ventricular myocytes from patients with terminal heart failure. Am Heart J 129:684–689PubMedCrossRef Beuckelmann DJ, Nabauer M, Kruger C, Erdmann E (1995) Altered diastolic [Ca2 +]i handling in human ventricular myocytes from patients with terminal heart failure. Am Heart J 129:684–689PubMedCrossRef
6.
Zurück zum Zitat Böhm M, Reil JC, Danchin N et al (2008) Association of heart rate with microalbuminuria in cardiovascular risk patients: data from I-SEARCH. J Hypertens 26:18–25PubMedCrossRef Böhm M, Reil JC, Danchin N et al (2008) Association of heart rate with microalbuminuria in cardiovascular risk patients: data from I-SEARCH. J Hypertens 26:18–25PubMedCrossRef
7.
Zurück zum Zitat Böhm M, Swedberg K, Komajda M et al (2010) Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 376:886–894PubMedCrossRef Böhm M, Swedberg K, Komajda M et al (2010) Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 376:886–894PubMedCrossRef
8.
Zurück zum Zitat Borer JS, Fox K, Jaillon P, Lerebours G (2003) Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation 107:817–823PubMedCrossRef Borer JS, Fox K, Jaillon P, Lerebours G (2003) Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation 107:817–823PubMedCrossRef
9.
Zurück zum Zitat Bowditch HP (1871) Über die Eigentümlichkeit der Reizbarkeit, welche die Muskelfasern des Herzens zeigen. Ber Sächs Ges (Akad) 652–689 Bowditch HP (1871) Über die Eigentümlichkeit der Reizbarkeit, welche die Muskelfasern des Herzens zeigen. Ber Sächs Ges (Akad) 652–689
10.
Zurück zum Zitat Communal C, Singh K, Sawyer DB, Colucci WS (1999) Opposing effects of beta(1)- and beta(2)-adrenergic receptors on cardiac myocyte apoptosis: role of a pertussis toxin-sensitive G protein. Circulation 100:2210–2212PubMed Communal C, Singh K, Sawyer DB, Colucci WS (1999) Opposing effects of beta(1)- and beta(2)-adrenergic receptors on cardiac myocyte apoptosis: role of a pertussis toxin-sensitive G protein. Circulation 100:2210–2212PubMed
11.
Zurück zum Zitat Cooney MT, Vartiainen E, Laatikainen T et al (2010) Elevated resting heart rate is an independent risk factor for cardiovascular disease in healthy men and women. Am Heart J 159:612–619 e613PubMedCrossRef Cooney MT, Vartiainen E, Laatikainen T et al (2010) Elevated resting heart rate is an independent risk factor for cardiovascular disease in healthy men and women. Am Heart J 159:612–619 e613PubMedCrossRef
12.
Zurück zum Zitat Custodis F, Baumhäkel M, Schlimmer N et al (2008) Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice. Circulation 117:2377–2387PubMedCrossRef Custodis F, Baumhäkel M, Schlimmer N et al (2008) Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice. Circulation 117:2377–2387PubMedCrossRef
13.
Zurück zum Zitat Custodis F, Gertz K, Balkaya M et al (2011) Heart rate contributes to the vascular effects of chronic mental stress: effects on endothelial function and ischemic brain injury in mice. Stroke 42:1742–1749PubMedCrossRef Custodis F, Gertz K, Balkaya M et al (2011) Heart rate contributes to the vascular effects of chronic mental stress: effects on endothelial function and ischemic brain injury in mice. Stroke 42:1742–1749PubMedCrossRef
14.
Zurück zum Zitat Custodis F, Schirmer SH, Baumhäkel M et al (2010) Vascular pathophysiology in response to increased heart rate. J Am Coll Cardiol 56:1973–1983PubMedCrossRef Custodis F, Schirmer SH, Baumhäkel M et al (2010) Vascular pathophysiology in response to increased heart rate. J Am Coll Cardiol 56:1973–1983PubMedCrossRef
15.
Zurück zum Zitat Diaz A, Bourassa MG, Guertin MC, Tardif JC (2005) Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 26:967–974PubMedCrossRef Diaz A, Bourassa MG, Guertin MC, Tardif JC (2005) Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 26:967–974PubMedCrossRef
16.
Zurück zum Zitat DiFrancesco D, Camm JA (2004) Heart rate lowering by specific and selective I-f current inhibition with ivabradine – A new therapeutic perspective in cardiovascular disease. Drugs 64:1757–1765PubMedCrossRef DiFrancesco D, Camm JA (2004) Heart rate lowering by specific and selective I-f current inhibition with ivabradine – A new therapeutic perspective in cardiovascular disease. Drugs 64:1757–1765PubMedCrossRef
17.
Zurück zum Zitat Dyer AR, Persky V, Stamler J et al (1980) Heart rate as a prognostic factor for coronary heart disease and mortality: findings in three Chicago epidemiologic studies. Am J Epidemiol 112:736–749PubMed Dyer AR, Persky V, Stamler J et al (1980) Heart rate as a prognostic factor for coronary heart disease and mortality: findings in three Chicago epidemiologic studies. Am J Epidemiol 112:736–749PubMed
18.
Zurück zum Zitat Ekman I, Chassany O, Komajda M et al (2011) Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure. Results from the SHIFT study. Eur Heart J 32:2395–2404PubMedCrossRef Ekman I, Chassany O, Komajda M et al (2011) Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure. Results from the SHIFT study. Eur Heart J 32:2395–2404PubMedCrossRef
19.
Zurück zum Zitat Ferrari R (2009) A step further with ivabradine: SIGNIFY (study assessing the morbidity-mortality benefits of the If inhibitor ivabradine in patients with coronary artery disease). Eur Heart J (Suppl 11):D19–D27 Ferrari R (2009) A step further with ivabradine: SIGNIFY (study assessing the morbidity-mortality benefits of the If inhibitor ivabradine in patients with coronary artery disease). Eur Heart J (Suppl 11):D19–D27
20.
Zurück zum Zitat Foody JM, Farrell MH, Krumholz HM (2002) beta-Blocker therapy in heart failure: scientific review. JAMA 287:883–889PubMedCrossRef Foody JM, Farrell MH, Krumholz HM (2002) beta-Blocker therapy in heart failure: scientific review. JAMA 287:883–889PubMedCrossRef
21.
Zurück zum Zitat Fox K, Ford I, Steg PG et al (2008) Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 372:807–816PubMedCrossRef Fox K, Ford I, Steg PG et al (2008) Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 372:807–816PubMedCrossRef
22.
Zurück zum Zitat Gibbons RJ, Abrams J, Chatterjee K et al (2003) ACC/AHA 2002 guideline update for the management of patients with chronic stable angina – summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 41:159–168PubMedCrossRef Gibbons RJ, Abrams J, Chatterjee K et al (2003) ACC/AHA 2002 guideline update for the management of patients with chronic stable angina – summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 41:159–168PubMedCrossRef
23.
Zurück zum Zitat Graham I, Atar D, Borch-Johnsen K et al; European Society of Cardiology (ESC) Committee for Practice Guidelines (CPG) (2007) European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 28:2375–2414PubMedCrossRef Graham I, Atar D, Borch-Johnsen K et al; European Society of Cardiology (ESC) Committee for Practice Guidelines (CPG) (2007) European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 28:2375–2414PubMedCrossRef
24.
Zurück zum Zitat Heidland UE, Strauer BE (2001) Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation 104:1477–1482PubMedCrossRef Heidland UE, Strauer BE (2001) Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation 104:1477–1482PubMedCrossRef
25.
Zurück zum Zitat Heusch G (2008) Heart rate in the pathophysiology of coronary blood flow and myocardial ischaemia: benefit from selective bradycardic agents. Br J Pharmacol 153:1589–1601PubMedCrossRef Heusch G (2008) Heart rate in the pathophysiology of coronary blood flow and myocardial ischaemia: benefit from selective bradycardic agents. Br J Pharmacol 153:1589–1601PubMedCrossRef
26.
Zurück zum Zitat Heusch G, Schulz R (2005) The pathophysiological role of heart rate in acute myocardial ischemia and the benefits of heart rate reduction. Taylor & Francis, London New York Heusch G, Schulz R (2005) The pathophysiological role of heart rate in acute myocardial ischemia and the benefits of heart rate reduction. Taylor & Francis, London New York
27.
Zurück zum Zitat Hjalmarson A, Gilpin EA, Kjekshus J et al (1990) Influence of heart rate on mortality after acute myocardial infarction. Am J Cardiol 65:547–553PubMedCrossRef Hjalmarson A, Gilpin EA, Kjekshus J et al (1990) Influence of heart rate on mortality after acute myocardial infarction. Am J Cardiol 65:547–553PubMedCrossRef
28.
Zurück zum Zitat Link A, Reil JC, Selejan S, Böhm M (2009) Effect of ivabradine in dobutamine induced sinus tachycardia in a case of acute heart failure. Clin Res Cardiol 98:513–515PubMedCrossRef Link A, Reil JC, Selejan S, Böhm M (2009) Effect of ivabradine in dobutamine induced sinus tachycardia in a case of acute heart failure. Clin Res Cardiol 98:513–515PubMedCrossRef
29.
Zurück zum Zitat McAlister FA, Wiebe N, Ezekowitz JA et al (2009) Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 150:784–794PubMed McAlister FA, Wiebe N, Ezekowitz JA et al (2009) Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 150:784–794PubMed
30.
Zurück zum Zitat Palatini P (2009) Elevated heart rate in cardiovascular diseases: a target for treatment? Prog Cardiovasc Dis 52:46–60PubMedCrossRef Palatini P (2009) Elevated heart rate in cardiovascular diseases: a target for treatment? Prog Cardiovasc Dis 52:46–60PubMedCrossRef
31.
Zurück zum Zitat Palatini P, Benetos A, Grassi G et al (2006) Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension Consensus Meeting. J Hypertens 24:603–610PubMedCrossRef Palatini P, Benetos A, Grassi G et al (2006) Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension Consensus Meeting. J Hypertens 24:603–610PubMedCrossRef
32.
Zurück zum Zitat Reil JC, Böhm M (2007) The role of heart rate in the development of cardiovascular disease. Clin Res Cardiol 96:585–592PubMedCrossRef Reil JC, Böhm M (2007) The role of heart rate in the development of cardiovascular disease. Clin Res Cardiol 96:585–592PubMedCrossRef
33.
Zurück zum Zitat Reil JC, Custodis F, Swedberg K et al (2011) Heart rate reduction in cardiovascular disease and therapy. Clin Res Cardiol 100:11–19PubMedCrossRef Reil JC, Custodis F, Swedberg K et al (2011) Heart rate reduction in cardiovascular disease and therapy. Clin Res Cardiol 100:11–19PubMedCrossRef
34.
Zurück zum Zitat Sajadieh A, Nielsen OW, Rasmussen V et al (2004) Increased heart rate and reduced heart-rate variability are associated with subclinical inflammation in middle-aged and elderly subjects with no apparent heart disease. Eur Heart J 25:363–370PubMedCrossRef Sajadieh A, Nielsen OW, Rasmussen V et al (2004) Increased heart rate and reduced heart-rate variability are associated with subclinical inflammation in middle-aged and elderly subjects with no apparent heart disease. Eur Heart J 25:363–370PubMedCrossRef
35.
Zurück zum Zitat Schirmer SH, Degen A, Baumhäkel M et al (2011) Heart-rate reduction by If-channel inhibition with ivabradine restores collateral artery growth in hypercholesterolemic atherosclerosis. Eur Heart J [Epub ahead of print] Schirmer SH, Degen A, Baumhäkel M et al (2011) Heart-rate reduction by If-channel inhibition with ivabradine restores collateral artery growth in hypercholesterolemic atherosclerosis. Eur Heart J [Epub ahead of print]
36.
Zurück zum Zitat Swedberg K, Komajda M, Böhm M et al (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376:875–885PubMedCrossRef Swedberg K, Komajda M, Böhm M et al (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376:875–885PubMedCrossRef
37.
Zurück zum Zitat Swedberg K, Viquerat C, Rouleau JL et al (1984) Comparison of myocardial catecholamine balance in chronic congestive heart failure and in angina pectoris without failure. Am J Cardiol 54:783–786PubMedCrossRef Swedberg K, Viquerat C, Rouleau JL et al (1984) Comparison of myocardial catecholamine balance in chronic congestive heart failure and in angina pectoris without failure. Am J Cardiol 54:783–786PubMedCrossRef
38.
Zurück zum Zitat Tardif JC, Ford I, Tendera M et al (2005) Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 26:2529–2536PubMedCrossRef Tardif JC, Ford I, Tendera M et al (2005) Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 26:2529–2536PubMedCrossRef
39.
Zurück zum Zitat Tardif JC, O’Meara E, Komajda M et al (2011) Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiographic substudy. Eur Heart J 32:2507–2515PubMedCrossRef Tardif JC, O’Meara E, Komajda M et al (2011) Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiographic substudy. Eur Heart J 32:2507–2515PubMedCrossRef
40.
Zurück zum Zitat Topalian S, Ginsberg F, Parrillo JE (2008) Cardiogenic shock. Crit Care Med 36:66–74CrossRef Topalian S, Ginsberg F, Parrillo JE (2008) Cardiogenic shock. Crit Care Med 36:66–74CrossRef
Metadaten
Titel
Herzfrequenz und Frequenzkontrolle
Prognostische Bedeutung bei kardiovaskulären Erkrankungen
verfasst von
Dr. F. Custodis
J.-C. Reil
U. Laufs
M. Böhm
Publikationsdatum
01.01.2012
Verlag
Springer-Verlag
Erschienen in
Die Innere Medizin / Ausgabe 1/2012
Print ISSN: 2731-7080
Elektronische ISSN: 2731-7099
DOI
https://doi.org/10.1007/s00108-011-2887-3

Weitere Artikel der Ausgabe 1/2012

Der Internist 1/2012 Zur Ausgabe

Schwerpunkt

Albuminurie

Mitteilungen der DGIM

Mitteilungen der DGIM

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.